Explore Business Standard
Taking paracetamol during pregnancy might increase the offspring's chances of developing neurodevelopmental disorders, including autism and attention deficit hyperactivity disorder, according to a study. Available over-the-counter, paracetamol -- also known as 'acetaminophen' -- is considered safe for managing headache, fever, and pain during pregnancy. Researchers, including those at the Icahn School of Medicine at Mount Sinai, US, analysed 46 previously published studies involving over a lakh participants across multiple countries. Findings published in the journal BioMed Central show that "higher-quality studies are more likely to show a link between prenatal acetaminophen exposure and increased risks of autism and ADHD," said author Diddier Prada, assistant professor of population health science and policy, environmental medicine and climate science, at the Icahn School of Medicine at Mount Sinai. "Given the widespread use of this medication, even a small increase in risk could
Glenmark Pharmaceuticals is recalling close to 15 lakh bottles of a generic medication used in the treatment of attention deficit hyperactivity disorder in the US market, according to the US health regulator. Glenmark Pharmaceuticals Inc, USA, a subsidiary of the Mumbai-based drug maker, is recalling around 14.76 lakh bottles of Atomoxetine Capsules in multiple strengths. The company is recalling the affected lot due to "CGMP Deviations", the US Food and Drug Administration (USFDA) said in its latest Enforcement Report. The recall is due to "presence of N-Nitroso Atomoxetine impurity above the FDA recommended limit," it added. New Jersey-based Glenmark Pharmaceuticals Inc, USA is recalling the made-in-India product in strengths ranging from 10 mg to 100 mg, USFDA stated. The company initiated the Class II recall on January 29 this year. As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medic
Drug firm Granules India on Tuesday said its subsidiary has received approval from the US health regulator for a generic medication used to treat attention-deficit hyperactivity disorder. Granules Pharmaceuticals, Inc (GPI) has received approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Lisdexamfetamine Dimesylate chewable tablets, the drug firm said in a statement. The approved drug is available in multiple strengths; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg, it added. The company's product is the generic equivalent to Takeda Pharmaceuticals' Vyvanse chewable tablets, the company said. The medication is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged six years and older, as well as moderate to severe binge eating disorder (BED) in adults. Lisdexamfetamine dimesylate chewable tablets are currently published on the FDA Drug Shortages List, emphasising ..